{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:48:42Z","timestamp":1787759322896,"version":"build-2784847793"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Carbapenem-resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> (CRAB)-caused severe pneumonia is associated with high mortality rates, and treatment options are limited. Tetracyclines, including tigecycline and omadacycline, have <jats:italic>in vitro<\/jats:italic> activity against CRAB. We conducted this study to explore the efficacy of omadacycline in CRAB-caused severe pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study was performed by collecting data on severe CRAB-caused pneumonia cases treated with omadacycline or tigecycline at Nanjing Drum Tower Hospital from January 2022 to June 2024. A 1:1 propensity score-based matching design based on baseline characteristics was utilized. We compared the incidence of clinical response at day 14 or at the end of treatment (EOT) and other clinical outcomes between the two cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 40 patients were analyzed, with 20 patients in each cohort. The clinical success rate at day 14 or at the EOT was 65% (13\/20) in the omadacycline group compared to 55% (11\/20) in the tigecycline group. Both groups had an equal mortality rate, with 8 patients dying within 28\u202fdays. Development of tigecycline resistance was observed in one patient. The average duration of invasive mechanical ventilation, vasopressor, renal replacement therapy was also comparable in both groups. Adverse events occurred in 50% (10\/20) of patients in the omadacycline group and 75% (15\/20) in the tigecycline group, with coagulopathy being significantly lower in the omadacycline group (1\/20, 5% vs. 7\/20, 35%). Gastrointestinal events were reported in 10% (2\/20) of the omadacycline group compared to 30% (6\/20) in the tigecycline group. Abnormal liver function was observed in 9\/20 patients (45%) in the omadacycline group and 6\/20 patients (30%) in the tigecycline group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This pilot study was the first to explore the efficacy and safety of omadacycline in CRAB-caused pneumonia. Omadacycline demonstrated comparable efficacy to tigecycline in this small pilot study in the treatment of CRAB-caused pneumonia and has a lower incidence of coagulopathy compared to tigecycline, suggesting it may be a viable option, for treating CRAB-caused severe pneumonia, but further prospective research with larger sample sizes is needed to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmicb.2025.1597860","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T05:35:45Z","timestamp":1753248945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A matched pilot cohort study of intravenous omadacycline in the treatment of severe pneumonia associated with carbapenem-resistant Acinetobacter baumannii"],"prefix":"10.3389","volume":"16","author":[{"given":"Dayu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3390\/antibiotics13060553","article-title":"Optimizing antibiotic therapy for Stenotrophomonas maltophilia infections in critically ill patients: a pharmacokinetic\/Pharmacodynamic approach","volume":"13","author":"Barrasa","year":"2024","journal-title":"Antibiotics (Basel)."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","article-title":"American college of chest physicians\/society of critical care medicine consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"20","author":"Bone","year":"1992","journal-title":"Crit. Care Med."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMe1900188","article-title":"Omadacycline - the newest tetracycline","volume":"380","author":"Chambers","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e46893","DOI":"10.7759\/cureus.46893","article-title":"Advancements in the Management of Severe Community-Acquired Pneumonia: a comprehensive narrative review","volume":"15","author":"Davis","year":"2023","journal-title":"Cureus."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/CCM.0000000000005804","article-title":"Surviving Sepsis campaign","volume":"51","author":"Dellinger","year":"2023","journal-title":"Crit. Care Med."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s10096-020-03877-w","article-title":"In vitro activity of omadacycline against pathogens isolated from mainland China during 2017-2018","volume":"39","author":"Dong","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.2147\/IDR.S384296","article-title":"Omadacycline for the treatment of severe Chlamydia psittaci pneumonia complicated with multiple organ failure: a case report","volume":"15","author":"Fang","year":"2022","journal-title":"Infect Drug Resist."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1089\/sur.2020.241","article-title":"Efficacy and tolerability of eravacycline in bacteremic patients with complicated intra-abdominal infection: a pooled analysis from the IGNITE1 and IGNITE4 studies","volume":"22","author":"Felice","year":"2021","journal-title":"Surg. Infect."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7936","DOI":"10.1038\/s41467-024-52166-z","article-title":"The evolution of heteroresistance via small colony variants in Escherichia coli following long term exposure to bacteriostatic antibiotics","volume":"15","author":"Gil-Gil","year":"2024","journal-title":"Nat. Commun."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e01135","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of Omadacycline and Tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1075185","DOI":"10.3389\/fcimb.2022.1075185","article-title":"A multicenter investigation of 2,773 cases of bloodstream infections based on China antimicrobial surveillance network (CHINET)","volume":"12","author":"Hu","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"116711","DOI":"10.1016\/j.diagmicrobio.2025.116711","article-title":"Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019-2023)","volume":"111","author":"Huband","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/IOP.0000000000001987","article-title":"Association of age-adjusted Charlson Comorbidity Index with Orbital Fungal Disease Outcomes","volume":"38","author":"Kupcha","year":"2022","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s40265-018-1015-2","article-title":"Omadacycline: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"ofad335","DOI":"10.1093\/ofid\/ofad335","article-title":"Long-term safety and tolerability of omadacycline for the treatment of Mycobacterium abscessus infections","volume":"10","author":"Mingora","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s40121-022-00645-5","article-title":"Real-world, multicenter case series of patients treated with Oral Omadacycline for resistant gram-negative pathogens","volume":"11","author":"Morrisette","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/jrpp.jrpp_50_24","article-title":"Carbapenem-resistant Acinetobacter baumannii and ventilator-associated pneumonia; epidemiology, risk factors, and current therapeutic approaches","volume":"13","author":"Najafabadi","year":"2024","journal-title":"J Res Pharm Pract."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/jac\/dku379","article-title":"Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis","volume":"70","author":"Nemeth","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/jac\/dkaa508","article-title":"In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii","volume":"76","author":"Noel","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1086\/381972","article-title":"Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections","volume":"38","author":"Pankey","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e02327","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY antimicrobial surveillance program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose","volume":"58","author":"Rodvold","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"ofab136","DOI":"10.1093\/ofid\/ofab136","article-title":"Clinical efficacy of patients with secondary bacteremia treated with omadacycline: results from phase 3 acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia studies","volume":"8","author":"Sakoulas","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jama.2024.14796","article-title":"Community-acquired pneumonia: a review","volume":"332","author":"Vaughn","year":"2024","journal-title":"JAMA"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/IDR.S393647","article-title":"High-dose Tigecycline for the treatment of progressive pneumonia caused by Chlamydia psittaci: case series and literature review","volume":"16","author":"Wang","year":"2023","journal-title":"Infect Drug Resist."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/idr13030076","article-title":"Inadequate cerebrospinal fluid concentrations of available salvage agents further impedes the optimal treatment of multidrug-resistant Enterococcus faecium meningitis and bacteremia","volume":"13","author":"Wenzler","year":"2021","journal-title":"Infect Dis Rep."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12890-025-03481-8","article-title":"Severe pneumonia due to concurrent legionella pneumophila and Acinetobacter baumannii infections: a case report","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Pulm. Med."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e9112","DOI":"10.1002\/rcm.9112","article-title":"Determination of tigecycline in human lung epithelial cells and polymorphonuclear neutrophils by liquid chromatography\/tandem mass spectrometry and its application in a cellular pharmacokinetics study","volume":"35","author":"Yang","year":"2021","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","article-title":"Omadacycline: a novel Oral and intravenous Aminomethylcycline antibiotic agent","volume":"80","author":"Zhanel","year":"2020","journal-title":"Drugs"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1597860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T05:35:46Z","timestamp":1753248946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1597860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":32,"alternative-id":["10.3389\/fmicb.2025.1597860"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1597860","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"article-number":"1597860"}}